Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.42 |
| ▸ | CA2 | P00918 | 9/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462173 | 0.97 | CA12 (0.43) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL13035533 | 0.90 | RPS6KA1 (0.35) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL3446583 | 0.88 | MTNR1A (0.43) | — | |
| SCHEMBL3446087 | 0.88 | CA1 (0.46) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL2679045 | 0.87 | MTNR1A (0.33) | — | |
| SCHEMBL3445550 | 0.85 | CA12 (0.44) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL463550 | 0.84 | LARS1 (0.44) | CA1CA2CA12CA9 | |
| SCHEMBL3447009 | 0.83 | MTNR1A (0.41) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL12674063 | 0.82 | CA12 (0.38) | CA1CA2CA12CA9SCN9A | |
| SCHEMBL5019552 | 0.81 | TP53 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251678-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-108610356-B | Benzoxaborole derivatives for the treatment of bacterial infections | 阿纳科制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20180016285-A1 | Boron-Containing Small Molecules | ANACOR PHARMACEUTICALS, LLC | 2018-01-18 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| EP-3251678-A1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Anacor Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2164331-B1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9796735-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9751898-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2613788-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20150133402-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2015-05-14 | — | — | US | disclosed |
| US-8895534-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7816344-B2 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2164331-A1 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2008157726-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | CA1 3768/4885CA2 732/4885CA12 875/4885 |
| US-20150133402-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | CA1 3768/4885CA2 732/4885CA12 875/4885 |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | CA1 4452/4885CA2 1021/4885CA12 483/4885 |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | OXA1L, TLR1, OXER1 | CA1 4867/4885CA2 4483/4885CA12 4785/4885 |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | CA1 4452/4885CA2 1021/4885CA12 483/4885 |
| US-20180016285-A1 | Boron-Containing Small Molecules | BCL6B, BLVRB, BCL6 | CA1 3768/4885CA2 732/4885CA12 875/4885 |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | CA1 4452/4885CA2 1021/4885CA12 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.